State Street’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-713,150
| Closed | -$72.7M | – | 4651 |
|
|
2023
Q2 | $72.7M | Buy |
713,150
+80,205
| +13% | +$7.59M | ﹤0.01% | 1434 |
|
|
2023
Q1 | $57.5M | Sell |
632,945
-52,047
| -8% | -$3.05M | ﹤0.01% | 1554 |
|
|
2022
Q4 | $26M | Sell |
684,992
-66,251
| -9% | -$2.28M | ﹤0.01% | 2049 |
|
|
2022
Q3 | $18.9M | Buy |
751,243
+9,530
| +1% | +$264K | ﹤0.01% | 2274 |
|
|
2022
Q2 | $22.5M | Buy |
741,713
+73,695
| +11% | +$2.2M | ﹤0.01% | 2164 |
|
|
2022
Q1 | $21.9M | Sell |
668,018
-596
| -0.1% | -$17.7K | ﹤0.01% | 2329 |
|
|
2021
Q4 | $17.6M | Buy |
668,614
+44,658
| +7% | +$3.46M | ﹤0.01% | 2567 |
|
|
2021
Q3 | $62.8M | Buy |
623,956
+34,467
| +6% | +$4.04M | ﹤0.01% | 1632 |
|
|
2021
Q2 | $83.4M | Buy |
589,489
+209,100
| +55% | +$23.6M | ﹤0.01% | 1440 |
|
|
2021
Q1 | $37.9M | Sell |
380,389
-2,870
| -0.7% | -$335K | ﹤0.01% | 1946 |
|
|
2020
Q4 | $47.4M | Sell |
383,259
-4,023
| -1% | -$529K | ﹤0.01% | 1668 |
|
|
2020
Q3 | $37.7M | Buy |
387,282
+26,005
| +7% | +$3.25M | ﹤0.01% | 1651 |
|
|
2020
Q2 | $56.4M | Sell |
361,277
-156,888
| -30% | -$23.8M | ﹤0.01% | 1380 |
|
|
2020
Q1 | $74.8M | Buy |
518,165
+7,394
| +1% | +$1.43M | 0.01% | 1007 |
|
|
2019
Q4 | $104M | Buy |
510,771
+46,003
| +10% | +$8.39M | 0.01% | 1022 |
|
|
2019
Q3 | $37.3M | Buy |
464,768
+6,728
| +1% | +$571K | ﹤0.01% | 1645 |
|
|
2019
Q2 | $43.2M | Buy |
458,040
+32,683
| +8% | +$2.82M | ﹤0.01% | 1574 |
|
|
2019
Q1 | $36.4M | Sell |
425,357
-19,763
| -4% | -$1.64M | ﹤0.01% | 1641 |
|
|
2018
Q4 | $25M | Buy |
445,120
+38,018
| +9% | +$2.32M | ﹤0.01% | 1835 |
|
|
2018
Q3 | $33.3M | Buy |
407,102
+89,891
| +28% | +$6.34M | ﹤0.01% | 1821 |
|
|
2018
Q2 | $11.1M | Buy |
317,211
+130,614
| +70% | +$3.98M | ﹤0.01% | 2489 |
|
|
2018
Q1 | $3.83M | Buy |
186,597
+8,629
| +5% | +$222K | ﹤0.01% | 2922 |
|
|
2017
Q4 | $5.04M | Buy |
177,968
+35,521
| +25% | +$991K | ﹤0.01% | 2788 |
|
|
2017
Q3 | $4.43M | Buy |
142,447
+34,235
| +32% | +$1.03M | ﹤0.01% | 2856 |
|
|
2017
Q2 | $3.42M | Buy |
108,212
+5,094
| +5% | +$125K | ﹤0.01% | 2922 |
|
|
2017
Q1 | $2.34M | Buy |
103,118
+2,704
| +3% | +$66.8K | ﹤0.01% | 3025 |
|
|
2016
Q4 | $2.19M | Buy |
100,414
+4,879
| +5% | +$123K | ﹤0.01% | 3070 |
|
|
2016
Q3 | $2.52M | Buy |
95,535
+32,124
| +51% | +$637K | ﹤0.01% | 2883 |
|
|
2016
Q2 | $1.25M | Buy |
+63,411
| New | +$1.23M | ﹤0.01% | 3204 |
|
Other funds holding RETA
State Street's RETA Position: Q3 2023 in Review
State Street sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 713,150 shares — an estimated $72.7M sold.
State Street first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $104M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- State Street reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- State Street sold 713,150 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $72.7M.
- State Street first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- State Street's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $104M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.